W. Dieterle

发表

Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients.

P. Degen, W. Theobald, W. Schneider, 1988, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics of clofazimine in healthy volunteers.

J. Dubois, W. Theobald, W. Dieterle, 1987, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

Biotransformation and pharmacokinetics of acenocoumarol (Sintrom®) in man

M. Sulc, J. Faigle, W. Theobald, 2004, European Journal of Clinical Pharmacology.

Binding of chlorthalidone (Hygroton®) to blood components in man

J. Faigle, W. Dieterle, J. Wagner, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly

A. Richens, J. Mcewen, W. Dieterle, 2004, European Journal of Clinical Pharmacology.

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.

W. Dieterle, J. Mann, S. Corynen, 2005, International journal of clinical pharmacology and therapeutics.

Development and validation of a disease-specific questionnaire on the quality of life of patients with chronic venous insufficiency.

M. Augustin, E. Schöpf, C. Brill, 1997, VASA. Zeitschrift fur Gefasskrankheiten.

Pharmacokinetics and Pharmacodynamics of the ETA‐Selective Endothelin Receptor Antagonist SPP301 in Healthy Human Subjects

W. Dieterle, J. Mann, K. Kutz, 2004, Journal of clinical pharmacology.

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.

W. Dieterle, J. Mann, S. Corynen, 2004, British journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria

C. Schweizer, W. Dieterle, G. Kaiser, 2004, European Journal of Clinical Pharmacology.

Species differences in the disposition and metabolism of sulfinpyrazone.

J. Faigle, W. Dieterle, 1981, Xenobiotica; the fate of foreign compounds in biological systems.

Influence of food on the disposition of the monoamine oxidase‐A inhibitor brofaromine in healthy volunteers

J. Cardot, P. Degen, W. Dieterle, 1993, Biopharmaceutics & drug disposition.

C-glucuronides, a novel type of drug metabolites.

W. Richter, T. Winkler, J. Faigle, 1975, Helvetica chimica acta.

Preparative reversed-phase chromatography of polar and non-polar metabolites on columns packed with micronized xad-2 resin

J. Faigle, W. Dieterle, H. Mory, 1979 .

Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.

W. Dieterle, J. Mann, 2006, International journal of clinical pharmacology and therapeutics.

Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine

W. Dieterle, G. Flesch, P. Lloyd, 1994, Epilepsia.

New metabolites of sulfinpyrazone in man.

J. Faigle, J. Moppert, W. Dieterle, 1980, Arzneimittel-Forschung.

The Metabolism and Pharmacokinetics of Clomipramine (Anafranil)

J. Faigle, W. Dieterle, 1973 .

Preparative Liquid-Chromatographic Methods in Drug Metabolism Studies

J. Faigle, W. Dieterle, 1983 .

Multiple inverse isotope dilution assay for oxprenolol and nine metabolites in biological fluids.

J. Faigle, W. Dieterle, 1983, Journal of chromatography.

The disposition and metabolism of 14C-oxprenolol.HCl in man.

J. Faigle, W. Theobald, W. Küng, 1986, Xenobiotica; the fate of foreign compounds in biological systems.

Multiple inverse isotope dilution assay for the stereospecific determination of R(+)- and S(-)-oxprenolol in biological fluids.

J. Faigle, W. Dieterle, 1983, Journal of chromatography.

Biotransformation of oxaprotiline: isolation and identification of metabolites in urine of rat and dog.

T. Winkler, J. Faigle, H. Kriemler, 1986, Xenobiotica; the fate of foreign compounds in biological systems.

The metabolic fate of 14C-oxaprotiline X HCl in man. III. Stereospecific disposition.

J. Faigle, W. Theobald, W. Küng, 1984, Biopharmaceutics & drug disposition.

Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.

S. Brechbühler, W. Dieterle, G. Kaiser, 1989, Biopharmaceutics & drug disposition.

Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry.

J. Dubois, W. Dieterle, G. Kaiser, 1987, Journal of chromatography.

Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan®) in man

W. Richter, J. Faigle, W. Theobald, 1975, European Journal of Clinical Pharmacology.

Disposition and Metabolism of Ralfinamide, a Novel Na-Channel Blocker, in Healthy Male Volunteers

M. Brunner, C. Leuratti, E. Lackner, 2010, Pharmacology.

Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.

W. Dieterle, J. Mann, K. Kutz, 2005, International journal of clinical pharmacology and therapeutics.

The biotransformation of phenylbutazone (Butazolidin).

J. Faigle, W. Dieterle, 1977, The Journal of international medical research.

Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers

P. Bieck, I. Reimann, W. Dieterle, 1992, Biopharmaceutics & drug disposition.

Determination of the antidepressant levoprotiline and its N-desmethyl metabolite in biological fluids by gas chromatography/mass spectrometry.

W. Dieterle, G. Kaiser, R. Ackermann, 1991, Biological mass spectrometry.